Nab-Paclitaxel

In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.

The addition of nab-paclitaxel to cisplatin-based concurrent chemoradiotherapy appeared effective for women with locally advanced cervical cancer, according to prospective study results.

In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.

In a video interview, Benjamin Schlechter, MD, talked about a “fascinating, compelling and important study” that looked at liposomal irinotecan injection regimen vs. nab-paclitaxel and gemcitabine in metastatic pancreatic cancer.

September is Ovarian Cancer Awareness Month.

The addition of famitinib to first-line camrelizumab and nab-paclitaxel appeared active among patients with immunomodulatory subtype advanced triple-negative breast cancer, according to results presented at the virtual ASCO Annual Meeting.

Evaluating recurrence score and Ki67 better defined subsequent treatment for women with hormone receptor-positive, HER2-negative early breast cancer, according to study results presented at the virtual San Antonio Breast Cancer Symposium.

The addition of atezolizumab to paclitaxel failed to significantly prolong PFS for patients with PD-L1-positive metastatic triple-negative breast cancer, according to phase 3 study results presented during ESMO Virtual Congress 2020.